Asia-Pacific Rapid Diagnostic Tests (RDT) Market, By Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy and Fertility Testing, Toxicology Testing, and Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Rapid Diagnostic Tests (RDT) Market Analysis and Size
The incidence of rapid diagnostic tests (RDTs) refers to the frequency or rate at which these tests are used or performed. However, it is important to note that the incidence of RDTs can vary greatly depending on the specific disease or condition being tested for, the geographic location, and the healthcare setting. The factors expected to drive the Asia-Pacific rapid diagnostic tests (RDT) market are the increase in incidence in chronic diseases, rise in geriatric population, technological developments in the rapid diagnostic tests. Moreover, the strategic initiatives by market players and the rise in healthcare expenditure are expected to create opportunities for the Asia-Pacific rapid diagnostic tests (RDT) market growth.
Data Bridge Market Research analyses that the Asia-Pacific rapid diagnostic tests (RDT) market which was USD 13,063.46 million in 2022, is expected to reach USD 28,412.60131 million by 2030, and is expected to undergo a CAGR of 10.2% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Rapid Diagnostic Tests (RDT) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Consumables and Kits, Instruments and Others), Mode (Professional Rapid Diagnostic Test Product and Over-The-Counter [OTC] Rapid Diagnostic Test Product), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy and Fertility Testing, Toxicology Testing, and Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2030
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott (U.S.), Danaher (U.S.), Cellex (U.S.), AdvaCare Pharma (China), Access Bio (U.S.), Cardinal Health (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux SA (France), InBios International, Inc. (U.S.), Gnomegen LLC (U.S.), QIAGEN (Netherlands), Quidel Corporation (U.S.), Chembio Diagnostics Systems, Inc. (U.S.), Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG) (Germany), PerkinElmer Inc. (U.S.), Sekisui Diagnostics (U.S.), Fujirebio (A Subsidiary of H.U. Group) (Japan), PTS Diagnostics (U.S.), LamdaGen Corporation (U.S.), Werfen (Spain), Nova Biomedical (U.S.), Trinity Biotech (Ireland), Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation) (Germany), Luminex Corporation. A DiaSorin Company (U.S.), MEGAKOR DIAGNOSTK GMBH (Germany)
|
|
Market Opportunities
|
|
Market Definition
The rapid diagnostic tests, also called rapid tests, are easy-to-use tests that offer quick results, usually in less than 20 minutes. Unlike other standard and conventional tests, where the diagnosis and sampling are sent to the laboratory, the results obtained from rapid diagnostic test kits are provided at the point of care. The point of care is a place where the patients get cured. The point of care can be a provider's office, a clinic, or a patient's own house.
Asia-Pacific Rapid Diagnostic Tests (RDT) Market Dynamics
Drivers
- Prevalence of Infectious Diseases
Asia-Pacific countries often face challenges related to infectious diseases, such as malaria, dengue, and various tropical illnesses. Rapid diagnostic tests are crucial in diagnosing these diseases quickly, leading to early treatment and containment, which drives the demand for RDTs in the region.
- Government Initiatives and Healthcare Investments
Many governments in the Asia-Pacific region have launched initiatives to control the spread of infectious diseases. These initiatives often include mass screening programs, which increase the demand for rapid diagnostic tests. Financial support and subsidies provided by governments further enhance the accessibility of these tests..
- Technological Advancements
Ongoing advancements in rapid diagnostic technologies, such as improved accuracy, ease of use, and the ability to test multiple diseases in a single device, are driving the adoption of RDTs. These innovations make the tests more reliable and efficient, encouraging both healthcare providers and individuals to opt for them.
- Rising Investment in Healthcare Infrastructure
Increasing investments in healthcare infrastructure, especially in developing countries within the Asia-Pacific region, lead to better healthcare facilities and services. This includes the availability of advanced diagnostic tools, including rapid tests, in hospitals, clinics, and remote healthcare centers.
Opportunities
- Expansion in Emerging Markets
Rapidly expanding healthcare infrastructure in emerging markets provides opportunities for RDT manufacturers to reach new regions, especially in rural areas with limited access to diagnostic facilities. In several Asia-Pacific countries, healthcare infrastructure is improving, leading to increased accessibility to diagnostic services. Penetration into these emerging markets with affordable and efficient RDTs can result in substantial market expansion.
- Technological Advancements
Ongoing advancements in rapid diagnostic technologies present a significant opportunity. Innovations such as smartphone-based testing apps and wearable devices for continuous monitoring are enhancing the market. Collaborations between technology companies and healthcare providers can lead to ground breaking developments.
- Home Testing from the Kits
Rising consumer preference for self-testing and home healthcare fosters the development of user-friendly RDTs for conditions like diabetes, cholesterol, and pregnancy, creating a market for home testing kits. There's a growing trend toward home-based healthcare, accelerated by the COVID-19 pandemic. RDTs that are easy to use at home for various conditions, from infectious diseases to chronic illnesses, present a vast market opportunity. Companies investing in user-friendly, reliable home test kits can capture this market.
Restraints/Challenges
- Regulatory Challenges
Stringent regulatory processes and varying standards across countries in the Asia-Pacific region pose challenges for RDT manufacturers, hindering market entry and growth. Different countries in the Asia-Pacific region have varied regulatory frameworks. Navigating these regulations, ensuring approvals, and maintaining quality standards can be a significant challenge for RDT manufacturers.
- Limited Sensitivity and Specificity
Some RDTs may have limitations in sensitivity and specificity compared to laboratory-based tests, impacting their reliability in certain diagnostic applications. Some RDTs, especially in emerging markets, might have accuracy issues. False positives or negatives can lead to misdiagnoses and inappropriate treatments, eroding trust in these tests.
- Price Sensitivity
Price sensitivity in healthcare budgets, especially in developing economies, challenges the affordability and widespread adoption of advanced RDTs, limiting market penetration. Despite advancements, some advanced RDTs can be costly. Affordability remains a challenge, especially in low-income regions where the target market might not be able to afford these tests regularly.
- Supply Chain Disruptions
Disruptions in the supply chain, as witnessed during the COVID-19 pandemic, can impact the availability and distribution of RDTs, leading to market challenges. The supply chain vulnerabilities exposed during the COVID-19 pandemic highlight potential challenges. Disruptions in the supply of critical components can hamper production and distribution, affecting the market.
This Asia-Pacific rapid diagnostic tests (RDT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific rapid diagnostic tests (RDT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2021, the Quidel Corporation had received emergency approval from the Food and Drug Administration (FDA) for the novel Sofia Q Rapid Antigen Test Device. The approval on an emergent basis was to add the Sofia Q in its latest addition of product range, along with Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA). The approval received would allow the Sofia Q rapid antigen test device to be used in telemedicine and home markets
- In August 2021, Cardinal Health partnered with Abbott and Quidel Corporation to commercialize the over-the-counter (OTC) rapid COVID-19 tests. The partnership would allow Cardinal Health to expand Cardinal Health's COVID-19 testing and surveillance offerings and be able to access Quidel's QuickVue At-Home OTC COVID-19 Test and Abbott's BinaxNOW COVID-19 Antigen Self-Test, which allow the patients to perform tests without prescription easily
Asia-Pacific Rapid Diagnostic Tests (RDT) Market Scope
The Asia-Pacific rapid diagnostic tests (RDT) market is segmented on the basis of product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application area's difference in your target markets.
Product Type
- Kits
- Instruments
- Others
Surgery
- Professional Rapid Diagnostic Test Product
- Over-The-Counter [OTC] Rapid Diagnostic Test Product
Technology
- PCR-Based Flow-Through Assays
- Lateral Flow Immunochromatographic Assays
- Agglutination Assay
- Microfluidics
- Substrate Technology
- Others
Modality
- Laboratory Based Test
- Non-laboratory Based Test
Age group
- Adult
- Pediatric
Test type
- Confirmation
- Serological Testing
- Viral Sequencing
Approach
- In-Vitro Diagnostic
- Molecular Diagnostic
Specimen
- Swab
- Blood
- Urine
- Saliva
- Sputum
- Others
Application
- Infectious Disease Testing
- Glucose Monitoring
- Cardiology Testing
- Oncology Testing
- Cardiometabolic Testing
- Drugs-of-Abuse Testing
- Pregnancy and Fertility Testing
- Toxicology Testing
- Others
End user
- Hospital and Clinic
- Diagnostic Laboratory
- Home Care Setting
- Research and Academic Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Asia-Pacific Rapid Diagnostic Tests (RDT) Market Regional Analysis/Insights
The Asia-Pacific rapid diagnostic tests (RDT) market is analysed, and market size information is provided by country, product type, mode, technology, modality, age group, test type, approach, specimen, application, end user, and distribution channel as referred above.
The countries covered in the Asia-Pacific rapid diagnostic tests (RDT) market report are Japan, China, India, South Korea, Australia, Singapore, Indonesia, Philippines, and the Rest of Asia-Pacific
China is expected to dominate and is fastest growing in the Asia-Pacific rapid diagnostic tests (RDT) market as it is one of the leading countries to inculcate rapid diagnostic tests (RDT) and products increases rapidly with urbanization and laboratory automation.
The country section of the Rapid Diagnostic Tests (RDT) Market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. The Rapid Diagnostic Tests (RDT) Market is analysed and market size insights and trends are provided by country, product, indication and end user as referenced above.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Asia-Pacific rapid diagnostic tests (RDT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Asia-Pacific rapid diagnostic tests (RDT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on Asia-Pacific rapid diagnostic tests (RDT) market. The data is available for historic period 2015-2020.
Competitive Landscape and Asia-Pacific Rapid Diagnostic Tests (RDT) Market Share Analysis
The Asia-Pacific rapid diagnostic tests (RDT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific rapid diagnostic tests (RDT) market.
Some of the major players operating in the Asia-Pacific rapid diagnostic tests (RDT) market are:
- Abbott (U.S.)
- Danaher (U.S.)
- Cellex (U.S.)
- AdvaCare Pharma (China)
- Access Bio (U.S.)
- Cardinal Health (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- bioMérieux SA (France)
- InBios International, Inc. (U.S.)
- Gnomegen LLC (U.S.)
- QIAGEN (Netherlands)
- Quidel Corporation (U.S.)
- Chembio Diagnostics Systems, Inc. (U.S.)
- Siemens Healthcare Gmbh (A Subsidiary Siemens Healthineers AG) (Germany)
- PerkinElmer Inc. (U.S.)
- Sekisui Diagnostics (U.S.)
- Fujirebio (A Subsidiary of H.U. Group) (Japan)
- PTS Diagnostics (U.S.)
- LamdaGen Corporation (U.S.)
- Werfen (Spain)
- Nova Biomedical (U.S.)
- Trinity Biotech (Ireland)
- Sysmex Europe GmbH (A Subsidiary of Sysmex Corporation) (Germany)
- Luminex Corporation. A DiaSorin Company (U.S.)
- MEGAKOR DIAGNOSTK GMBH (Germany)
SKU-